EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Nutritional Status Indicators Predict Tolerability to Adjuvant Chemotherapy in Patients with Stage II/III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy

Shinya Abe, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Hiroyuki Matsuzaki, Yuzo Nagai, Takahide Shinagawa, Hirofumi Sonoda, Soichiro Ishihara

Digestion · 2024

DOI: 10.1159/000539211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestion, 2024. Verfasst von Shinya Abe und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Rectal Neoplasms, Nutritional Status, Neoadjuvant Therapy, Neoplasm Staging. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Adjuvant chemotherapy (AC) after radical surgery following preoperative chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC) is now the standard of care. The identification of risk factors for the discontinuation of AC is important for further improvements in survival. We herein examined the prognostic impact of chemotherapy compliance and its relationship with the prognostic nutritional index (PNI) before surgery.

Methods

A total of 335 stage II–III LARC patients who underwent preoperative CRT between 2003 and 2022 at the University of Tokyo Hospital were retrospectively reviewed. We excluded patients with recurrence during AC and those who had not received AC. The relationship between AC and long-term outcomes and that between PNI values and the duration of AC were examined.

Results

Thirty-one patients discontinued AC and 62 continued AC. Recurrence-free survival (RFS) was significantly shorter in patients who discontinued AC (p = 0.0056). The discontinuation of AC was identified as an independent risk factor for RFS (hazard ratio [HR]: 2.24, p = 0.0233). Twenty-one patients were classified as having low PNI (less than 40), which correlated with an older age, low body mass index, and incomplete AC. Low PNI was an independent risk factor for a shorter duration of AC (HR: 2.53, p = 0.0123).

Conclusion

The discontinuation of AC was related to poor RFS in patients with LARC undergoing preoperative CRT. Furthermore, a low PNI value was identified as a risk factor for a shorter duration of AC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsNutritional StatusNeoadjuvant TherapyNeoplasm StagingNutrition AssessmentHumansFemaleMaleMiddle AgedRetrospective StudiesAgedChemotherapy, AdjuvantRisk FactorsAdultDisease-Free SurvivalPrognosisTreatment OutcomeNeoplasm Recurrence, LocalAged, 80 and over

Stichwörter der Autor:innen

Colorectal cancerOutcomePostoperative chemotherapyProgressive nutritional index

Autor:innen und Institutionen

  • Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Zitieren

APA

Abe, S., Nozawa, H., Sasaki, K., Murono, K., Emoto, S., Yokoyama, Y., Matsuzaki, H., Nagai, Y., Shinagawa, T., Sonoda, H., & Ishihara, S. (2024). Nutritional Status Indicators Predict Tolerability to Adjuvant Chemotherapy in Patients with Stage II/III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy. Digestion. https://doi.org/10.1159/000539211

Vancouver

Abe S, Nozawa H, Sasaki K, Murono K, Emoto S, Yokoyama Y, et al. Nutritional Status Indicators Predict Tolerability to Adjuvant Chemotherapy in Patients with Stage II/III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy. Digestion. 2024. doi:10.1159/000539211

BibTeX
@article{Abe2024,
  author = {Abe, Shinya and Nozawa, Hiroaki and Sasaki, Kazuhito and Murono, Koji and Emoto, Shigenobu and Yokoyama, Yuichiro and Matsuzaki, Hiroyuki and Nagai, Yuzo and Shinagawa, Takahide and Sonoda, Hirofumi and Ishihara, Soichiro},
  title = {Nutritional Status Indicators Predict Tolerability to Adjuvant Chemotherapy in Patients with Stage II/III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy},
  journal = {Digestion},
  year = {2024},
  doi = {10.1159/000539211}
}
Kostenlos starten →